C3N-04162
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 46.81451061
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V2+0.410
- MYC_TARGETS_V1+0.300
- KRAS_SIGNALING_DN+0.290
- INTERFERON_ALPHA_RESPONSE+0.220
- APICAL_SURFACE+0.200
- SPERMATOGENESIS+0.190
- MITOTIC_SPINDLE+0.120
- MTORC1_SIGNALING+0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- KRAS_SIGNALING_UP-0.390
- ANGIOGENESIS-0.360
- IL2_STAT5_SIGNALING-0.360
- ANDROGEN_RESPONSE-0.350
- HYPOXIA-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- PROTEIN_SECRETION-0.350
- COMPLEMENT-0.340
- NOTCH_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03272 | — | cohortSQ2 | 0.868 |
| 2 | 2d8478f6-41ac-47f5-ac3c-337af7245f5b | — | — | 0.867 |
| 3 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.854 |
| 4 | TCGA-LL-A7T0-01A-31R-A352-07 | — | B | 0.853 |
| 5 | SRR8518168 | — | E | 0.836 |
| 6 | TCGA-NC-A5HR-01A-21R-A26W-07 | — | cohortSQ2 | 0.826 |
| 7 | BS_YEW22W35 | high-grade glioma | — | 0.820 |
| 8 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.816 |
| 9 | TCGA-B6-A0RL-01A-11R-A084-07 | — | B | 0.815 |
| 10 | C3L-03678 | — | cohortSQ1 | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.030 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |